infliximab news

All news on infliximab (also known as REMICADE): plants, production capacities, investments and involved companies.

15 July 2026

Johnson & Johnson Q2 2026 results and raises 2026 outlook

Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.

Who will be producing infliximab in the future?

Find out with chemXplore Alpha

Learn more